YKP 581

Drug Profile

YKP 581

Alternative Names: YKP581

Latest Information Update: 10 Jul 2009

Price : $50

At a glance

  • Originator Johnson & Johnson; SK Bio-Pharmaceuticals
  • Developer Johnson & Johnson; SK Drug Development Center
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Major depressive disorder

Most Recent Events

  • 11 Oct 2005 Phase-I clinical trials in Depression in Europe (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top